Also. . .

GlaxoSmithKline won Food and Drug Administration approval to market its blockbuster antidepressant Paxil for a new use--treating general anxiety disorder. That makes Paxil the first drug in its class to win approval for the condition, which affects roughly 10 million Americans and is marked by excessive, often debilitating worrying, the company said. Paxil already is approved for use in treating depression, obsessive-compulsive disorder, social phobia and panic disorder. With 2000 sales of $2.4 billion, Paxil was the world’s seventh-best-selling drug in 2000. GlaxoSmithKline’s American depositary receipts closed up 5 cents at $26.05 on the NYSE.